Carsten Boess
Director/Board Member at ROCKET PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Karl Peggs | M | 57 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 years |
| Troy Wilson | M | 55 | 12 years | |
| Edwin Moses | M | 69 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
| Lars Fruergaard Jorgensen | M | 58 | 33 years | |
| Stephen Biggar | M | 53 | 13 years | |
| Eben Tessari | M | 42 | 10 years | |
| Iraj Ali | M | 48 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
| David Southwell | M | 63 | 10 years | |
| Barry Quart | M | 67 | 12 years | |
| Sarah Boyce | F | 52 | 5 years | |
| Eric B. Mosbrooker | M | 46 | 3 years | |
| John Militello | M | 50 | 6 years | |
| Derek DiRocco | M | 43 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 4 years |
| Michael Megna | M | 53 | 6 years | |
| Rod Wong | M | 47 | 6 years | |
| Mark Ragosa | M | 50 | 6 years | |
| Kathleen Gallagher | F | - | 3 years | |
| Arthur Levin | M | 70 | 11 years | |
| Gaurav D. Shah | M | 49 | 6 years | |
| John W. Wallen | M | 66 | 12 years | |
| Sanj Patel | M | 54 | 9 years | |
| Michael Giordano | M | 66 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
| Tracey McCain | F | 56 | 6 years | |
| Felix Baker | M | 55 | 9 years | |
| Kinnari Patel | M | 46 | 6 years | |
| Sergio Quezada | M | 49 | 4 years | |
| Martin Wilson | M | 47 | 3 years | |
| Jonathan Schwartz | M | 60 | 8 years | |
| R. Woods | M | 57 | 1 years | |
| Melissa Manno | F | - | 9 years | |
| Gayatri R. Rao | M | - | 6 years | |
| Tamar Thompson | F | 50 | 3 years | |
| Daniel Hood | M | - | - | |
| Noreen Henig | M | 59 | 5 years | |
| Mark White | M | 57 | 1 years | |
| Kim Popovits | F | 65 | 6 years | |
| Thomas Malley | M | 55 | 8 years | |
| Edward Kaye | M | 74 | 5 years | |
| Richard Levy | M | 66 | 5 years | |
| Pedro Granadillo | M | 77 | 6 years | |
| Naveen Yalamanchi | M | 47 | 6 years | |
| Jean J. Kim | F | 50 | 3 years | |
| Michael MacLean | M | 58 | 4 years | |
| Gotham Makker | M | 50 | 6 years | |
| Bernhard R. M. Ehmer | M | 69 | 2 years | |
| Henrik Ehlers Wulff | M | 54 | 25 years | |
| Karsten Munk Knudsen | M | 53 | 25 years | |
| Fady Malik | M | 59 | 2 years | |
| Margareta Elisabeth Björk | M | 63 | 4 years | |
| Tariq Ahmed | M | - | 4 years | |
| Edward Samuel | M | - | 2 years | |
| Liz Elmhirst | F | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Shree Patel | M | - | - | |
| James Taylor | M | - | 2 years | |
| Robert Coutts | M | 40 | 4 years | |
| Carlos Martin | M | - | - | |
| Ross Moat | M | 43 | 5 years | |
| Rogier Rooswinkel | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Dara Henry | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Martin Lange | M | 54 | 22 years | |
| Martina Struck | M | - | 6 years | |
| Martin Murphy | M | 55 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Julie O'Neill | F | 58 | 3 years | |
| Steven G. Hughes | M | 57 | 2 years | |
| Katrine Sperling | F | - | 22 years | |
| Camilla Sylvest | F | 52 | 28 years | |
| Elisa Petris | M | 45 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 years |
| Maziar Mike Doustdar | M | 54 | 32 years | |
| John Paolini | M | 59 | 8 years | |
| Brooks Rahmer | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christopher Heberlig | M | 49 | 12 years | |
| Thomas Beetham | M | 55 | 8 years | |
| Stephen Mahoney | M | 53 | 7 years | |
| Brian Batchelder | M | - | - | |
| Mayur Kasetty | M | - | 4 years | |
| Rasmus Holm-Jorgensen | M | 53 | 11 years | |
| Jakob Riis | M | 58 | 21 years | |
| Todd Brady | M | 45 | 5 years | |
| Deirdre O’Donnell | F | - | - | |
| Brendan Classon | M | - | - | |
| Allison Dorval | F | 48 | 7 years | |
| Michael Martin | M | 50 | 5 years | |
| Lynn A. Taylor | F | - |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | - |
| Mark Goldberg | M | 69 | 6 years | |
| Thomas Tisch | M | 69 | 3 years | |
| Steven T. Sobieski | M | 66 | 10 years | |
| Carsten Hellmann | M | 60 | - | |
| Joseph Zakrzewski | M | 60 | 9 years | |
| John T. Garibotto | M | 59 | 8 years | |
| Mads Krogsgaard Thomsen | M | 63 | 30 years | |
| Jesper Brandgaard | M | 60 | 20 years | |
| Sten Scheibye | M | 72 | 10 years | |
| Kurt Anker Nielsen | M | 78 | 13 years | |
| Stephen Davis | M | 63 | 4 years | |
| Peter Wirth | M | 73 | 3 years | |
| Sally Crawford | F | 70 | 13 years | |
| Lars Robert Boesgaard | M | 55 | 5 years | |
| Larry L. Mathis | M | 80 | 10 years | |
| Regina Sommer | F | 66 | 9 years | |
| Claudine Prowse | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 68 | 68.00% |
| United Kingdom | 19 | 19.00% |
| Denmark | 13 | 13.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carsten Boess
- Personal Network
